摘要
目的:探究免疫治疗在宫颈癌中的作用机制以及对PD-1/PD-L1信号通路的影响,为患者治疗的疗效及其机制提供参考。方法:收集2017年12月~2019年1月在我院进行治疗的97例宫颈癌患者的临床病历资料进行回顾性分析。所有患者根据治疗方案的异同分为观察组(41例)和对照组(56例)。对照组患者接受常规放疗治疗,观察组患者则在上述基础上行免疫治疗。对比两组患者的临床疗效、外周血PD-1、PD-L1阳性表达以及T淋巴细胞亚群表达。结果:观察组患者的总有效率为65.85%,明显高于对照组(42.86%),差异比较有统计学意义。治疗前,两组患者的外周血PD-1、PD-L1水平以及CD3+、CD4+、CD8+及CD4+/CD8+水平比较均无统计学意义。治疗后,两组患者的外周血PD-1、PD-L1水平均明显低于治疗前,观察组患者的血PD-1、PD-L1水平均明显低于同期对照组。治疗后,观察组患者的CD3+、CD4+、CD8+及CD4+/CD8+水平均明显高于治疗前和同期对照组。结论:抗PD-1/PD-L1免疫疗法能够有效阻断PD-1/PD-L1信号通路,显著增强机体的抗肿瘤免疫功能,使肿瘤细胞无法逃避机体的免疫监视和杀伤。抗PD-1/PD-L1免疫疗法是临床治疗宫颈癌的新策略,仍需大量的研究来进一步证实。
Objective To research the mechanism of immunotherapy in cervical cancer and its effect on PD-1/PD-L1 signaling pathway.Method The clinical data of 97 cases of cervical cancer treated in our hospital from December 2017 to January 2019 were retrospectively analyzed.According to the different treatment schemes,they were divided into observation group(41 cases)and control group(56 cases).The patients in the control group received conventional radiotherapy,while the patients in the observation group received immunotherapy on the basis of the above.The clinical efficacy,the positive expression of PD-1 and PD-L1 in peripheral blood and the expression of T lymphocyte subsets were compared between the two groups.Result The total effective rate of the observation group was 65.85%,which was significantly higher than that of the control group(42.86%),the difference was statistically significant.Before treatment,there was no significant difference in the levels of PD-1,PD-L1,CD3+,CD4+,CD8+and CD4+/CD8+in peripheral blood between the two groups.After treatment,the levels of PD-1 and PD-L1 in peripheral blood of the two groups were significantly lower than those before treatment,and the levels of PD-1 and PD-L1 in the observation group were significantly lower than those in the control group at the same time.After treatment,the levels of CD3+,CD4+,CD8+and CD4+/CD8+in the observation group were significantly higher than those in the control group before treatment and at the same time.Conclusion Anti-PD-1/PD-L1 immunotherapy can effectively block the PD-1/PD-L1 signaling pathway,significantly enhance the anti-tumor immune function of the body,so that cancer cells can not escape the immune surveillance and killing of the body.Anti-PD-1/PD-L1 immunotherapy is a new strategy for clinical treatment of cervical cancer,which requires a lot of research to further confirm.
作者
孙晓华
Sun Xiao-hua(Department of Obstetrics and Gynecology,Maternal and Child Health Hospital of Qinhuangdao City,Qinhuangdao 066000,China)
出处
《晓庄学院学报（医学版）》
2020年第6期35-38,共4页
Journal of Hunan Normal University(Medical Sciences)
基金
秦皇岛市科技局项目(NO.201502A140)
